-
HMD received AAC license offer from Via more than seven years prior to Fraunhofer’s UPC complaint
Read more: HMD received AAC license offer from Via more than seven years prior to Fraunhofer’s UPC complaintA Unified Patent Court order denying an extension of time for HMD’s answer to Fraunhofer’s complaint reveals that Via already made a licensing offer in 2017.
-
Acer seeking counterleverage against Nokia through “threat letters” in U.S. despite highly asymmetric SEP portfolios and sales volumes: DJ action
Read more: Acer seeking counterleverage against Nokia through “threat letters” in U.S. despite highly asymmetric SEP portfolios and sales volumes: DJ actionAcer sent “threat letters” to U.S. telecommunications carriers using Nokia equipment, provoking a declaratory judgment complaint.
-
Via LA’s automotive Qi licensing glass is half-full as Korean supplier BH EVS joins wireless charging patent pool
Read more: Via LA’s automotive Qi licensing glass is half-full as Korean supplier BH EVS joins wireless charging patent poolVia LA’s Qi patent pool has now licensed approximately 50% of the global automotive supplier market.
-
Oura escalates Ultrahuman patent dispute with more patents and accusations of editing Wikipedia page to accuse Oura of patent trolling
Read more: Oura escalates Ultrahuman patent dispute with more patents and accusations of editing Wikipedia page to accuse Oura of patent trollingThe patent dispute between smart-ring pioneer Oura and Ultrahuman is getting dirty, with Oura accusing Ultrahuman of having edited its Wikipedia page and impersonated its CEO.
-
Stanford retains cancer detection patents licensed to Foresight Diagnostics, but Roche gets non-exclusive license: settlement
Read more: Stanford retains cancer detection patents licensed to Foresight Diagnostics, but Roche gets non-exclusive license: settlementRoche Molecular Systems, Stanford and Foresight Diagnostics have recently settled a dispute over trade secrets, breach of contract, unfair competition and patent ownership.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
Read more: Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costsAstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.
Follow Us
Latest Articles
- Latest amendment to Tokyo District Court’s SEP rules: global license requirement compared to latest UPC, UK, German, Brazilian approaches
- UPC Roundup (1 week): 4G action consolidated with later-filed 5G complaint against same party; Hague LD finds no UPC jurisdiction over BYD UK; more
- Eyeing the AI data center boom, Via Licensing Alliance unveils new NAND pool, issues call for patents
- Ibex sues Disney and Snap in Brazil as streaming patent disputes escalate
- Brazilian court lifts ZTE’s 5G injunction against Samsung as expert rejects infringement and essentiality claims